Education
About Us
Working with TipRanks
Follow Us
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H (HK:1541)
:1541
1541 Stock Chart & Stats
Day’s Range― - ―
52-Week RangeHK$4.31 - HK$16.80
Previous CloseN/A
Volume6.41M
Average Volume (3M)3.92M
Market Cap
HK$11.58B
Enterprise ValueHK$4.28B
Total Cash (Recent Filing)HK$703.70M
Total Debt (Recent Filing)HK$153.72M
Price to Earnings (P/E)―
Beta1.13
Next Earnings
Mar 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.40
Shares Outstanding396,277,300
10 Day Avg. Volume2,391,840
30 Day Avg. Volume3,924,401
Financial Highlights & Ratios
PEG Ratio0.29
Price to Book (P/B)2.69
Price to Sales (P/S)24.65
P/FCF Ratio-13.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$11.00Price Target Upside-24.81% Downside
Rating ConsensusHold
Number of Analyst Covering0
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H News
1541 FAQ
What was ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H’s price range in the past 12 months?
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H lowest stock price was HK$4.31 and its highest was HK$16.80 in the past 12 months.
What is ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H’s market cap?
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H’s market cap is HK$11.58B.
When is ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H’s upcoming earnings report date?
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H’s upcoming earnings report date is Mar 31, 2026 which is in 171 days.
How were ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H’s earnings last quarter?
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H released its earnings results on Aug 26, 2025. The company reported -HK$0.404 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.404.
Is ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H overvalued?
According to Wall Street analysts ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H’s price is currently Overvalued.
Does ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H pay dividends?
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H does not currently pay dividends.
What is ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H’s EPS estimate?
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H have?
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H has 396,277,300 shares outstanding.
What happened to ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H’s price movement after its last earnings report?
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H reported an EPS of -HK$0.404 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.298%.
Which hedge fund is a major shareholder of ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H?
Currently, no hedge funds are holding shares in HK:1541
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
HK$11.00 (-24.81% Downside)
HK$11.00 (-24.81% Downside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
―
20 days / 200 days
Momentum
100.41%
12-Months-Change
Fundamentals
Return on Equity
-53.23%
Trailing 12-Months
Asset Growth
5.79%
Trailing 12-Months
Company Description
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H (1541) is a biopharmaceutical company focused on the research, development, and commercialization of innovative cancer immunotherapy products. The company operates within the biotechnology sector, utilizing its proprietary technologies to develop a pipeline of cutting-edge therapies designed to harness the body's immune system to target and eliminate cancer cells. ImmuneOnco is dedicated to advancing its product candidates through clinical trials with the goal of providing new treatment options for patients with unmet medical needs.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H (1541) Earnings & Revenues
Technical Analysis
Ascletis Pharma, Inc.
―
Lepu Biopharma Co. Ltd. Class H
―
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
―
CStone Pharmaceuticals
―
Shandong Boan Biotechnology Company., Limited. Class H
―